The EpiVacCorona vaccine has arrived in a number of regions of Russia for research

"The EpiVacCorona vaccine, developed by the Vector Research Center of Rospotrebnadzor, has been delivered to medical organizations in Moscow, the Moscow region, the Tyumen region, the Kaliningrad region and the Republic of Tatarstan for post-registration clinical trials," the message says.

It is noted that clinical sites have begun recruiting volunteers.

In total, 4000 volunteers will take part in the selection, 3000 will be admitted to the research. 

Earlier it was reported that "EpiVacCorona" will go into civil circulation before the end of the year.